Network Point-of-Care Glucose Testing Market Size & Growth Forecast 2027–2036, By Segments (Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Network Point-of-Care Glucose Testing Market size was worth USD 1.5 billion in 2026 and is expected to grow at a 4.18% CAGR between 2027 and 2036, exceeding USD 2.26 billion by 2036. The industry revenue for 2027 is estimated at USD 1.55 billion.
Get more details on this report
Request Free Sample ReportNetwork Point-of-Care Glucose Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 43.14% share due to advanced digital health infrastructure, widespread hospital adoption, and strong integration of glucose testing devices with electronic medical records.
- Asia Pacific is growing at 5.13% CAGR driven by healthcare modernization, expanding hospital networks, and increasing adoption of connected point-of-care testing systems for faster clinical decision-making.
Segment Momentum
- Accu-Chek Inform II leads the market because its established use in hospital and clinical workflows delivers reliable connectivity, standardized operation, and smooth integration into networked point-of-care testing environments.
- CareSens Expert Plus is growing fastest as healthcare providers increasingly prioritize workflow flexibility, connected testing efficiency, and easy integration into digitally managed point-of-care testing processes.
Market Expansion Drivers
- Rising diabetes prevalence driving demand for rapid decentralized glucose monitoring solutions.
- Increasing adoption of remote patient monitoring systems improving real-time diabetes management outcomes.
- Expansion of digital health infrastructure enabling connected diagnostic device integration across care networks.
Leading Market Participants
- Key companies in the network point-of-care glucose testing market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Nova Biomedical Corporation (United States), Ascensia Diabetes Care Holdings AG (Switzerland), Nipro Corporation (Japan), ACON Laboratories, Inc. (United States), Prodigy Diabetes Care, LLC (United States), Siemens Healthineers AG (Germany), LifeScan, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.5 billion
- 2027 Estimated Market Size: USD 1.55 billion.
- Projected Market Size: USD 2.26 billion by 2036
- Growth Forecast: 4.18% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Accu-Chek Inform II (Product)
- Emerging Opportunity Segment: CareSens Expert Plus (Product)
Market Growth Drivers and Industry Trends
Rising diabetes prevalence driving demand for rapid decentralized glucose monitoring solutions
Increasing diabetes prevalence is driving the network point-of-care glucose testing market as healthcare providers require faster and more accessible methods for monitoring blood glucose levels outside centralized laboratory settings. Decentralized testing enables glucose measurements to be performed closer to patients, supporting timely clinical assessment and treatment decisions in hospitals, outpatient facilities, community care settings, and other healthcare environments. The need for convenient monitoring is particularly important for patients requiring regular glucose assessment, while healthcare systems benefit from reducing delays associated with laboratory-based testing. Greater emphasis on accessible chronic disease management is therefore encouraging the deployment of rapid glucose testing capabilities across distributed points of care.
Increasing adoption of remote patient monitoring systems improving real-time diabetes management outcomes
Integration of connected monitoring technologies with chronic disease care is creating additional demand for the network point-of-care glucose testing market, as remote patient monitoring enables healthcare professionals to track glucose-related information beyond traditional clinical visits. Connected testing systems can facilitate the transmission of patient readings to care teams, allowing abnormal measurements and changes in glucose patterns to be identified more promptly. This supports more continuous diabetes management and can improve coordination between patients and healthcare providers. As remote care models become increasingly integrated into routine disease management, glucose testing devices capable of supporting timely data collection and communication are gaining relevance within distributed healthcare networks.
Expansion of digital health infrastructure enabling connected diagnostic device integration across care networks
Investment in digital health infrastructure is expanding opportunities for the network point-of-care glucose testing market by creating the connectivity needed to integrate diagnostic devices with broader healthcare information systems. Modern care networks increasingly depend on interoperable platforms that can collect, transmit, and organize patient-generated diagnostic information across multiple locations. Connected glucose testing devices can contribute to these systems by providing near-real-time measurements that are accessible to authorized healthcare professionals and incorporated into patient management workflows. Improvements in digital connectivity, device integration, and healthcare data exchange are supporting broader deployment of point-of-care diagnostics within coordinated care environments.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising diabetes prevalence driving demand for rapid decentralized glucose monitoring solutions | 2.00% | High | Asia Pacific, Middle East & Africa | High | Near Term |
| Increasing adoption of remote patient monitoring systems improving real-time diabetes management outcomes | 1.80% | High | North America, Europe | High | Mid Term |
| Expansion of digital health infrastructure enabling connected diagnostic device integration across care networks | 1.50% | Moderate | North America, Asia Pacific | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for 43.14% of the network point-of-care glucose testing market in 2026, supported by advanced healthcare infrastructure, widespread adoption of connected medical technologies, and strong demand for decentralized diagnostic solutions. Network-enabled glucose testing facilitates faster access to patient information and supports more coordinated monitoring across clinical environments. Growing emphasis on chronic disease management, remote data accessibility, and efficient healthcare workflows is encouraging healthcare providers to integrate connected point-of-care testing into routine patient care.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing regional market, supported by expanding healthcare infrastructure, rising demand for diabetes monitoring, and increasing adoption of digital health technologies. Improving access to point-of-care diagnostics is creating opportunities for network-connected testing solutions in hospitals, clinics, and other healthcare settings. Greater investment in healthcare digitization and increasing demand for timely diagnostic information are also supporting wider adoption of connected glucose testing technologies across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Digitized clinical integrationIn Germany, adoption of network point-of-care glucose testing is shaped by structured healthcare systems prioritizing interoperability with hospital IT infrastructure. Clinical users in Germany focus on standardized data transmission and accuracy, particularly in diabetes management programs across outpatient and hospital-linked care pathways.
France 🇫🇷
Structured diabetes pathwaysIn France, network point-of-care glucose testing is increasingly embedded in structured diabetes care pathways across primary and specialist settings. Healthcare facilities in France prioritize system compatibility and reliable data capture to support coordinated long-term patient monitoring.
Italy 🇮🇹
Primary care modernizationIn Italy, expansion of point-of-care glucose testing networks is linked to modernization of primary care services and chronic disease monitoring. Healthcare providers in Italy focus on cost-efficient, connected systems that improve workflow efficiency in outpatient diabetes management.
Japan 🇯🇵
Aging care monitoring systemsIn Japan, demand is driven by aging population care models where networked glucose testing supports frequent monitoring in clinics and eldercare settings. Healthcare providers in Japan prioritize compact, reliable devices with seamless connectivity to centralized patient management platforms.
South Korea 🇰🇷
Smart clinic connectivityIn South Korea, rapid digitization of healthcare services is supporting wider use of connected point-of-care glucose testing in clinics and community health centers. Providers in South Korea emphasize real-time data transfer and integration with digital health platforms for improved chronic disease management efficiency.
United States 🇺🇸
Distributed chronic care adoptionIn the U.S., network-enabled point-of-care glucose testing is increasingly integrated into primary care and diabetes management programs, supporting decentralized monitoring across clinics and home-linked care networks. Providers in the U.S. emphasize connectivity with electronic health records and streamlined data sharing for continuous patient oversight.
Segment Leadership and Growth Trends
Network Point-of-Care Glucose Testing Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Accu-Chek Inform II (Largest Segment) vs CareSens Expert Plus (Fastest-Growing Segment)
The accu-chek inform II product segment held the largest position in the network point-of-care glucose testing market in 2026. Its strong market presence reflects the importance of reliable glucose testing within hospitals and other clinical environments where timely results support patient monitoring and treatment decisions. Network-enabled testing systems can improve the flow of glucose measurements into clinical workflows, reducing manual data handling and supporting more coordinated patient management. Increasing emphasis on efficient point-of-care diagnostics and connected healthcare environments continues to reinforce demand for established glucose testing solutions.
The CareSens expert plus product segment is gaining momentum as healthcare providers increasingly seek convenient and connected approaches to glucose monitoring. Demand for point-of-care systems is supported by the need for rapid testing, streamlined clinical workflows, and efficient access to patient results. Greater adoption of digital healthcare processes and connected diagnostic environments is creating opportunities for products that integrate glucose measurement with broader clinical information management, supporting faster uptake of emerging solutions.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | i-STAT, Accu-Chek Inform II, StatStrip, HemoCue, CareSens Expert Plus, BAROzen H Expert Plus | Accu-Chek Inform II | CareSens Expert Plus |
Competitive Landscape and Market Positioning
Key companies in the network point-of-care glucose testing market:
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Nova Biomedical Corporation (United States)
4. Ascensia Diabetes Care Holdings AG (Switzerland)
5. Nipro Corporation (Japan)
6. ACON Laboratories Inc. (United States)
7. Prodigy Diabetes Care LLC (United States)
8. Siemens Healthineers AG (Germany)
9. LifeScan Inc. (United States)
The network point-of-care glucose testing market is evolving through digital integration that enhances real-time diagnostic connectivity and patient monitoring. Expansion into emerging healthcare settings is broadening accessibility of testing solutions. Research advancements are improving accuracy, speed, and usability of glucose testing systems.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Nova Biomedical Corporation (United States) | |||||||
| Ascensia Diabetes Care Holdings AG (Switzerland) | |||||||
| Nipro Corporation (Japan) | |||||||
| ACON Laboratories Inc. (United States) | |||||||
| Prodigy Diabetes Care LLC (United States) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| LifeScan Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Glooko | Jun-26 | Glooko introduced an insulin pump settings EHR integration enabling device-agnostic visualization of basal rates and insulin-to-carbohydrate ratios directly within electronic health record systems. The solution enhances clinical decision-making by improving interoperability between diabetes devices and hospital data infrastructure. |
| Abbott | May-26 | Abbott received CE Mark approval for Libre Duo and Libre Duo 10 Day, dual glucose-ketone biowearable sensors capable of continuous monitoring of both biomarkers from a single device. The approval expands Abbott’s multi-analyte monitoring capabilities in the European diabetes management market. |
| Glooko | May-26 | Glooko obtained FDA 510(k) clearance for EndoTool IV Cloud, a cloud-based insulin dosing platform designed for hospital use. The solution supports automated insulin management workflows and strengthens digital therapeutics integration within inpatient diabetes care settings. |
| Trividia Health | Feb-26 | Trividia Health issued a Class I recall for TRUE METRIX Blood Glucose Monitoring Systems due to an E-5 error code labeling issue. The recall impacts multiple regions and reflects regulatory action to ensure accuracy and safety in point-of-care glucose monitoring devices. |
| Ascensia Diabetes Care | Jan-26 | Ascensia Diabetes Care transferred Eversense CGM commercialization rights to Senseonics, completing the U.S. transition in January 2026 with European transition expected by June 2026. The restructuring shifts commercial responsibilities for continuous glucose monitoring devices within the diabetes technology ecosystem. |
| Meta | Jun-25 | Introduced generative AI video editing capabilities across Meta AI app and related platforms, enabling transformation of video content using AI prompts for style, setting, lighting, and narrative effects, supporting broader AI-driven content creation workflows. |
| Cartwheel | May-25 | Launched a 3D animation AI tool suite that converts video, text, and motion libraries into production-ready 3D animations, enabling streamlined editing and integration into film, gaming, advertising, and digital content pipelines. |
| Abbott Laboratories | Jun-24 | Abbott Laboratories received FDA clearance for Libre Rio and Lingo over-the-counter glucose monitoring devices. Libre Rio targets type 2 diabetes patients not using insulin, while Lingo provides continuous glucose tracking with personalized metabolic insights, expanding access to consumer-focused glucose monitoring solutions. |
| Google LLC | May-24 | Introduced AI-powered advertising and search enhancements, including generative search experiences and tools enabling advertisers to create animated ads from still images with customizable branding elements for improved engagement and personalization. |
| Autodesk | May-24 | Acquired Wonder Dynamics to integrate AI-enabled cloud-based 3D animation and VFX tools into its production ecosystem, strengthening end-to-end digital content creation capabilities across media and entertainment workflows. |
| Kartoon Studios, Inc. | Apr-24 | Launched an AI-powered animation toolkit designed to improve production efficiency and content quality by integrating generative AI into animation workflows for enhanced creative output and streamlined studio operations. |
| Nova Biomedical | Mar-24 | Nova Biomedical launched its next-generation StatStrip Glucose Hospital Meter System with FDA 510(k) clearance. The system introduces enhanced cybersecurity, RFID-enabled data entry, wireless charging, and ruggedized design to improve accuracy, connectivity, and operational reliability in critical care glucose testing environments. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Network Point-of-Care Glucose Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| End User | Hospitals & Clinics, Physician Offices, Ambulatory Care Centers, Long-Term Care Facilities, Emergency Medical Services |
| Purchase Model | Capital Equipment Purchase, Reagent Rental/Placement, Managed Testing Services, Consumables-Based Contracts |
| Connectivity & Data Integration | Standalone Systems, Wireless Connectivity, Wired/LAN Connectivity, Integrated Hospital Information Systems, Cloud-Based Data Management |
Network Point-of-Care Glucose Testing Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Connected Diabetes Care Ecosystem Analysis |
|
| Healthcare Workflow Integration Assessment |
|
| Patient-Centric Monitoring Adoption Study |
|
Need a different cut of the data?
Request Custom ResearchHow large is the network point-of-care glucose testing market?
What is the expected industry size of network point-of-care glucose testing by 2036?
How is rising diabetes prevalence shaping demand for networked point-of-care glucose testing solutions?
Why is digital health infrastructure critical to scaling connected glucose testing across healthcare networks?
Why is Accu-Chek Inform II the leading product in the network point-of-care glucose testing market?
Why is CareSens Expert Plus the fastest-growing product in the network point-of-care glucose testing market?
Why does North America lead the network point-of-care glucose testing market?
What is driving Asia Pacific’s growth in this market?
Who holds a significant market share in the network point-of-care glucose testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization